Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for treatment of liver cancer

The receptor for advanced glycation-end prod-ucts (RAGE) has been shown to play a central role not only in acute or chronic inflammatory diseases but also in septic shock, late diabetes and cancer. Here we provide a new application of RAGE inhibition in the field of cancer prevention and treatment.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Sea slugs inspire highly stretchable biomedical sensor

USC Viterbi School of Engineering researcher Hangbo Zhao presents findings on highly stretchable and customizable microneedles for application in fields including neuroscience, tissue engineering, and wearable bioelectronics. The revolution in…

Twisting and binding matter waves with photons in a cavity

Precisely measuring the energy states of individual atoms has been a historical challenge for physicists due to atomic recoil. When an atom interacts with a photon, the atom “recoils” in…

Nanotubes, nanoparticles, and antibodies detect tiny amounts of fentanyl

New sensor is six orders of magnitude more sensitive than the next best thing. A research team at Pitt led by Alexander Star, a chemistry professor in the Kenneth P. Dietrich…

Partners & Sponsors